

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
				01-270
				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/786998
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				
INTERNATIONAL APPLICATION NO. PCT/EP99/06298		INTERNATIONAL FILING DATE 27 August 1999 (27.08.99)		PRIORITY DATE CLAIMED 14 September 1998 (14.09.98)
TITLE OF INVENTION USE OF AN ANTHRACYCLINE DERIVATIVE FOR THE TREATMENT OF A LIVER TUMOR				
APPLICANT(S) FOR DO/EO/US PACCIARINI, Maria Adele; VALOTA, Olga; KERR, David;				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p> <p>8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.</p> <p>9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</p> <p>12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p>				
<p>Items 13 to 20 below concern document(s) or information included:</p> <p>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>17. <input type="checkbox"/> A substitute specification.</p> <p>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>19. <input type="checkbox"/> Certificate of Mailing by Express Mail</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p>				
<p>Patent Data Sheet; Postcard; Check for the Amount of \$ 1340.00 ; Published International Application;</p> <div style="border: 1px solid black; height: 100px; width: 100%;"></div>				

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.491)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09786998	PCT/EP99/06298	01-270

21. The following fees are submitted.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$970.00
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$840.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$690.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$670.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)	\$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	19 - 20 =	0	x \$18.00	\$0.00
Independent claims	9 - 3 =	6	x \$80.00	\$480.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00
			TOTAL OF ABOVE CALCULATIONS =	\$1,340.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	\$0.00
			SUBTOTAL =	\$1,340.00
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).			<input type="checkbox"/> 20 <input type="checkbox"/> 30 +	\$0.00
			TOTAL NATIONAL FEE =	\$1,340.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	\$0.00
			TOTAL FEES ENCLOSED =	\$1,340.00
			Amount to be: refunded	\$
			charged	\$

A check in the amount of **\$1,340.00** to cover the above fees is enclosed.


Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **13-2490** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Stephen H. Docter
McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Suite 3200
Chicago, IL 60606
United States of America
Telephone (312) 913 - 0001
Fax (312) 913 - 0002



SIGNATURE

Stephen H. Docter

NAME

44,659

REGISTRATION NUMBER

13 March 2001

DATE

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments and consider the following remarks.

IN THE CLAIMS:

Claims 2-12 and 15-17 have been rewritten as follows:

2. (Amended) The use according to claim 1 wherein the liver tumor is a tumor primarily confined to the liver.

3. (Amended) The use according to claim 2 wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. (Amended) The use according to claim 1 wherein the tumor is a liver metastasis.

5. (Amended) The use according to claim 1 wherein the intrahepatic administration of MMDX is via the hepatic artery.

6. (Amended) The use according to claim 1 wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

7. (Amended) The use according to claim 1 wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

8. (Amended) The use according to claim 1 wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

9. (Amended) The use according to claim 8 wherein the agent is iodized oil.

10. (Amended) The use according to claim 1 wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

11. (Amended) The use according to claim 10 wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 800 mcg/m².

12. (Amended) The use according to claim 11 wherein the dose is 200 mcg/m².

15. (Amended) The use of a pharmaceutical composition according to claim 13 for the treatment of a liver tumor.

16. (Amended) The use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.

17. (Amended) The use according to claim 16 wherein the agent is iodized oil.


REMARKS

Applicants respectfully request the Examiner to enter this Preliminary Amendment.

Claims 2-12, and 15-17 have been rewritten to remove multiple dependencies and to more particularly point out the subject matter Applicants consider the invention. A marked-up copy of the claims showing all the changes is submitted herewith. No new matter has been added by these amendments. Support for the amendments is found in the specification as originally filed. With these amendments, the claims pending are 1-19.

Applicants respectfully solicit allowance of the claims as amended and passage of the case to issuance. If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (312) 913-0001

Respectfully submitted,



Stephen H. Docter, Registration No. 44,659
One of the Attorneys for Applicant(s)
McDonnell, Boehnen, Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001 (telephone)
(312) 913-0003 (facsimile)

Date: March 13, 2001

Marked-up Version of Claims 2-12 and 15-17

2. (Amended) The use according to claim 1, wherein the liver tumor is a tumor primarily confined to the liver.

3. (Amended) The use according to claim 2, wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. (Amended) The use according to claim 1, wherein the tumor is a liver metastasis.

5. (Amended) The use according to claim 1 ~~any one of the preceeding claims~~ wherein the intrahepatic administration of MMDX is via the hepatic artery.

6. (Amended) The use according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

7. (Amended) The use according to ~~anyone of claims 1 to 6~~, wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

8. (Amended) The use according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

9. (Amended) The use according to claim 8, wherein the agent is iodized oil.

10. (Amended) The use according to claim 1 ~~any one of the preceeding claims~~ wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

11. (Amended) The use—according to claim 10: wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 800 mcg/m².

12. (Amended) The use—according to claim 11: wherein the dose is 200 mcg/m².

15. (Amended) The use—of a pharmaceutical composition according to claim 13, or 14, for the treatment of a liver tumor.

16. (Amended) The use—of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.


17. (Amended) The use—according to claim 16 wherein the agent is iodized oil.

USE OF AN ANTHRACYCLINE DERIVATIVE FOR THE TREATMENT OF A LIVER TUMOR

5

The present invention relates to the use of methoxymorpholino doxorubicin for the treatment of a liver cancer; in particular, it refers to the intrahepatic administration of methoxymorpholino doxorubicin for use in the liver tumor 10 therapy.

Methoxymorpholino doxorubicin (MMDX, internal code PNU 152243) of formula



15 is a new doxorubicin derivative obtained with the substitution of the -NH₂ at position 3' in the sugar moiety with a methoxymorpholino group. The compound was synthesized in the course of a research program aimed at identifying new anthracyclines with at least partially novel modes of action, and possessing broad spectrum of activity, including activity 20 on multidrug resistant (mdr) tumors.

MMDX is active *in vitro* and *in vivo* on tumor cells resistant to anthracyclines and presenting the mdr phenotype, this last mechanism being recognized to occur also in man.

No cross-resistance was observed on tumor cells resistant to L-PAM or cDDP, or on cells resistant to Topoisomerase II inhibitors (at-mdr).

MMDX is active after i.p., i.v. or oral administration, with 5 good antitumor activity on murine leukemias, and on solid murine and human tumor models.

The compound differs from most anthracyclines in being highly potent when administered *in vivo*, the optimal i.v. dose being at least 80 fold less than that of doxorubicin. This result, 10 and the observation that the cytotoxic activity of MMDX is increased *in vitro* in the presence of mouse, rat and human liver microsomes, suggest that MMDX may be transformed into highly cytotoxic metabolite(s).

A well known pathway of the metabolic transformation of the 15 antitumor anthracyclines in mammals is the side-chain carbonyl group reduction, giving the corresponding 13-dihydro derivative. The reduced derivative of MMDX maintains activity *in vitro* and *in vivo* against doxorubicin-resistant models, at doses however 10 fold higher as compared to the parent drug.

20 The high lipophilicity of the molecule, which confers to the compound the ability to reach high intracellular concentrations and is most likely one of the reasons of its efficacy on resistant models, makes it effective also after oral administration. The oral antitumor efficacy of MMDX has 25 been examined in a panel of different tumor types with various schedules of administration. The results demonstrate that the oral treatment with MMDX is associated, in all the animal models examined, with an antitumor activity comparable to that observed after intravenous (i.v.) administration. In 30 these models, the effective oral doses of MMDX are 1.3-2 fold higher than the effective i.v. doses. In particular, in liver metastases from M5076 murine fibrosarcoma, the best result

(doubling of survival time) was achieved with the oral formulation, administered daily for 5 days; the injectable formulation was less effective. This might be a reflection of a different behaviour of the drug, due to first pass effect 5 to the liver.

It is well know that there is currently no effective conventional treatment for patient with primary hepatocellular carcinoma (HCC) and cholangiocarcinoma invading the liver.

10 In addition, the liver is a common site of metastasis in many human cancers.

Primary Liver Cancer

Tumors of the liver are among the most common malignancies in the world. The annual international incidence of the disease 15 is approximately 1 million cases, with a male to female ratio of approximately 4:1. There are 1.2 million deaths per year world wide. There is a huge geographic variation incidence corresponding to 2/100,000 in North America to 30/100,000 in South East Asia, although these numbers refer often to 20 "total liver cancer", without a differentiation between primary and secondary.

The highest incidence of liver cancer is seen in the Far East and is associated with high endemic hepatitis B carrier rates, contamination of foodstuffs, stored grains, drinking 25 water and soil. Advances in the management of these malignancies will likely depend on immunization strategies for hepatitis B and C and on developing a means of decreasing cirrhosis of any origin. Cirrhosis is frequently associated with HCC, especially in Europe and USA. Systemic 30 chemotherapy is generally disappointing, with response rate averaging less than 20%. Anthracyclines remain the most widely used agents. Mitomycin C is also used.

A wide variety of both surgical and nonsurgical therapies have become available for HCC. Surgical resection and orthotopic transplantation are the only curative options, but it is estimated that less than 10% of patients are suitable for this 5 approach and long-term results are poor. The low resectability and the high recurrent rate (40% in five years after surgery), together with the fact that HCC tends to be fatal because of local hepatic progression rather than widespread metastasis, stimulated the development of several 10 locoregional therapeutic approaches, including intra-arterial chemotherapy. Higher response rates appear to be reported for intra hepatic artery (IHA) chemotherapy administered along with embolizing agents, such as LIPIODOL™, gel foam and degradable starch microspheres. This approach is increasingly 15 used in the Far East. Anthracyclines (doxorubicin and epirubicin) are widely used in this setting. However, no substantial improvement in survival is obtained with current chemotherapy attempts. The need for new effective treatments remains high.

20 Secondary Liver Cancer

Liver is a common site of metastasis in many human cancers and hepatic involvement is often the major cause of morbidity and mortality in disseminated malignancy. In particular, the liver, by virtue of the portal venous 25 drainage system, is usually the first - and may be the only - site of metastases in many patients with primary colorectal cancer. Gastric and pancreatic cancers - but also melanoma, lung and breast cancers - may also frequently metastasize to the liver. Metastatic liver tumors are often the first 30 evidence of the progression of a patient's cancer, and particularly in colorectal cancer are the only tumors detected. Colorectal carcinoma is a disease of industrialized

nations. It is estimated that in USA over 160,000 new cases were diagnosed yearly and that 75,000 deaths occurred as a result of the advanced disease. Epidemiological studies show that the incidence of colorectal carcinoma is increasing.

5 Involvement of the liver is found in 40-70% of patients with progressive disease and liver is the sole site of initial tumor recurrence in up to 30% of patients with metastatic disease. Left untreated, metastatic lesions to the liver from colorectal cancers are associated with survival of 3 to 24

10 months.

For patients with isolated liver metastases, surgical resection is the best treatment option, with 20-30% 5 year survival rate. Surgery is only possible in about 10% of cases and it is estimated that up to 25% of patients undergoing surgical resection will recur with metastatic liver cancer.

15 Palliation with systemic chemotherapy is currently offered to most patients with extensive or multiple liver metastases. To date, systemic 5-fluoruracil (5-FU) plus folinic acid is considered the optimum treatment for metastatic colorectal 20 cancer, yielding response rates of only 20% and overall survival of around 12 months. Irinotecan hydrochloride trihydrate is the standard treatment after failure of 5-FU leucovorin, with a response rate of 15% and median survival time of approximately 9 months. Clinical trials are ongoing 25 with the objective to determine the role of irinotecan as first-line treatment in combination with 5-FU leucovorin.

In case the disease is confined to the liver and it is inoperable, regional intraarterial chemotherapy may be indicated. With the hepatic arterial infusion of 5-FU or of 30 its analogue, 5-fluorodeoxyuridine (FUDR), attempts have been made to maximise the clinical outcome (response rate in up to 50% of cases) but with no substantial effect on survival.

MMDX represents a therapeutic option in the treatment of a liver cancer.

The expectation that MMDX is effective in liver neoplasms comes from the findings of phase I and phase Ib studies

5 conducted by intravenous route, where, out of 30 patients evaluable for response in liver, 5 experienced regressions of liver metastases. Two patients with colorectal cancer had a <50% regression of liver lesions after 3 cycles, two patients with renal cancer showed a regression greater than 50% in

10 liver lesions after 3 cycles of treatment and an additional patient with colorectal cancer and multiple liver metastases at entry (subsequently dead from pulmonary embolism after the first cycle of treatment) showed no evidence of liver metastases at autopsy. Tumor shrinkage occurred at doses of 15 1250 and 1500 mcg/m² i.v.. Main toxicities were nausea and vomiting (requiring intravenous antiemetic treatment), myelosuppression and transient elevations in transaminases.

In addition, in a phase II study by i.v. route in breast cancer patients with liver metastases (previously untreated 20 for the advanced disease), 1 complete response, 3 partial responses (one of them not confirmed four weeks apart) and 1 minor response were observed in liver lesions of six patients treated (at 1500 mcg/m² i.v.).

These findings suggest an interesting affinity of MMDX for 25 liver lesions, even in tumor types resistant to conventional chemotherapy such as colorectal cancer and renal cancer.

Strong evidence of antitumor efficacy in liver is also supported by preclinical data. Activity of MMDX against liver metastases from M5076 murine reticulosarcoma is higher after 30 oral administration as compared to the i.v. route, suggesting that a first pass effect may favour the efficacy in liver. In

addition, MMDX administered orally is more effective on the liver metastases than on the solid primary in the same model. This specific effect on liver metastases is probably due to metabolite(s) produced by liver enzymes. This hypothesis is

5 reinforced by several results showing MMDX being activated in vitro by liver microsomes to a highly cytotoxic product. This metabolic conversion is believed to occur also in humans.

The hints of activity observed in the current clinical experience, coupled with the activity of MMDX in mdr models and in liver metastasis models, raise the expectation of an improved clinical outcome for patients with hepatic neoplastic lesions.

It would be therefore desirable to establish drug delivery strategies to avoid the high i.v. dosages of MMDX presently believed to have an antitumor activity at the hepatic level and to improve the antitumor efficacy of MMDX against a primary liver cancer and liver metastases.

There is a need to achieve high MMDX concentration at the hepatic tumor site, while reducing systemic exposure and hence toxicity.

The present invention fulfills such a need by providing a new method for administration of MMDX to a patient suffering from a liver tumor which reduces the MMDX amount without decreasing the MMDX's antitumor activity at the hepatic tumor site by directly injecting MMDX into the hepatic artery.

It is therefore a first object of the present invention the use of MMDX in the preparation of a medicament for the treatment of a human liver tumor which comprises intrahepatic administration of MMDX.

30 It is a further object of the present invention a method of treating a human liver tumor which comprises the intrahepatic

administation of a therapeutically effective amount of MMDX to a patient in need thereof.

It is a still further object of the present invention a method for reducing MMDX systemic exposure of a patient 5 suffering from a liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to said patient.

According to the present invention, a liver tumor can be a tumor primarily confined to the liver such as, e.g. an 10 hepatocellular carcinoma or a cholangiocarcinoma, or a liver metastase.

Preferably, the intrahepatic administration of MMDX is performed via the hepatic arthery.

In a particular embodiment of the invention, MMDX is 15 administered via the hepatic arthery, for example, as an infusion of from about 15 minutes to about 30 minutes every 4 weeks, or as a 5-10 minute bolus every 8 weeks, to adult patients with either a hepatic metastatic cancer, for example, patients with colorectal cancer who have progressed 20 after receiving intravenous chemotherapy or intrahepatic 5-fluorouracil or 5-fluorodeoxyuridine (FUDR) chemotherapy, or patients with previously untreated primary liver carcinoma such as, for example, hepatocellular carcinoma or cholangiocarcinoma involving the liver.

25 In a more particular embodiment of the present invention, MMDX is administered to a patient in a dosage ranging from, e.g., about 100 mcg/m² to about 1000 mcg/m², preferably from about 100 mcg/m² to about 800 mcg/m², for example in a dosage of about 200 mcg/m².

30 In a still more particular embodiment of the present invention, the appropriate dose of MMDX, preferably previously dissolved in saline solution, is mixed with a

suitable amount of an agent which remains selectively in a liver tumor after its injection through the hepatic artery. Preferably, the amount of this agent, for example iodized oil (LIPIODOL[®]), may vary from about 3 ml to about 20 ml,
5 depending on the tumor size.

LIPIODOL[®] is a lipid lymphographic agent which has been found to remain selectively in liver tumor after its injection through the hepatic artery so it is particularly useful as a carrier of anticancer agents.

10 The following table illustrates the suitable LIPIODOL[®] volumes referred to tumor size.

Table

Tumor size (cm)	LIPIODOL [®] volume (ml)
>= 2	3-5
2.1-6	5-8
6.1-11	9-14
>11	15-20

15 The administration dosage of MMDX will vary depending upon the disease status of the patient.

The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to
20 changes in conditions and/or in light of other clinical conditions.

For example, for intrahepatic therapy, freeze-dried vials containing 500 mcg of MMDX is diluted with 5 ml of sterile saline for injection to obtain a MMDX concentration of 100
25 mcg/ml. The appropriate dose of MMDX to be given to the

patient is optionally mixed with a suitable amount of LIPIODOL®.

The active drug can be administered directly into the lateral entry of an i.v. line inserted into the bung of an 5 intrahepatic portacath lying beneath the upper anterior abdominal wall. The drug can administered, for example, over 30 minutes infusion in a volume of 100 ml of normal saline. Flushing of the device with 10-20 ml of saline can be done to assure that all the drug is given. Patients who do not have a 10 portacath have a catheter inserted into the hepatic artery by a femoral Seldinger approach and the drug can be infused, for example, over 30 minutes infusion in a volume of 100 ml of normal saline. The catheter is inserted under local anesthesia and can then be removed from the groin, a pressure 15 bandage applied and nursing observations continued overnight in hospital.

Object of this invention is also to provide a pharmaceutical composition comprising MMDX as the active substance, in association with a pharmaceutically acceptable agent, as 20 defined above, which remains selectively in a liver tumor after its intrahepatic injection, for example through the hepatic artery, and one or more pharmaceutically acceptable excipients and/or carriers. The pharmaceutical compositions are usually prepared following conventional methods and are 25 administered in a pharmaceutically suitable form. For instance, solutions for intrahepatic injection or infusion may contain as a carrier, for example, sterile water or preferably, they may be in the form of sterile aqueous isotonic saline solutions.

30 The following Experimental Protocol illustrates but do not limit the present invention.

EXPERIMENTAL PROTOCOL

A single arm, multicentre, dose-finding Phase I study of MMDX (PNU 152243) administered as a brief infusion of 30 minutes every 4 weeks via the hepatic artery (IHA) to adult patients either with hepatic metastatic colorectal cancer who have progressed after receiving intravenous chemotherapy or intrahepatic 5-fluoruracil chemotherapy, or with previously untreated primary hepatocellular carcinoma or cholangiocarcinoma involving the liver was carried out. Their disease was confined to the liver, at the time of trial entry. Patients may have already had an intrahepatic portacath in situ or have the drug administered via the hepatic artery by a femoral Seldinger approach.

The primary goal of this study was the determination of Maximal Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLTs) of MMDX when administered via the hepatic artery.

Antitumor activity was documented in this study.

The starting dose was 100 mcg/m², corresponding to one third of the LD₁₀ in rats.

On a total of 23 registered patients, 18 received intra hepatic artery (IHA) administration of MMDX.

Doses tested ranged from 100 mcg/m² to 800 mcg/m².

Results are available on 13 patients: 3 patients (6 cycles) at 100 mcg/m², 3 patients (12 cycles) at 200mcg/m², 3 patients (4 cycles) at 400 mcg/m², 3 patients (10 cycles) at 600 mcg/m² and 1 patient (3 cycles) at 800 mcg/m².

Hematological toxicity

Grade 1 leucopenia was observed in 1 patient at 100 mcg/m² (1 cycle), 1 patient (1 cycles) at 200 mcg/m² and 1 patient (1 cycle) at 400 mcg/m². AGC were however always normal. Grade 1-2 thrombocytopenia occurred in 1 patient (3 cycles) at 200 mcg/m² and in 1 patient (1 cycle) at 600 mcg/m² and were

considered tumor related (HCC patients). Max. grade 1 anemia was reported in three patients at 200, 600 and 800 mcg/m², respectively.

Non-hematological toxicity

5 The most frequently observed adverse events, attributable to the study drug were nausea, vomiting and fatigue.

At 100 mcg/m²: mild vomiting was reported in one out of three patients (in 1 cycle); grade 1-2 fatigue was present in 2 patients (3 cycles).

10 At 200 mcg/m²: grade 2 nausea in 2 patients (2 cycles), grade 1-2 vomiting in 2 patients (3 cycles) and grade 2 fatigue in 1 patient (2 cycles) were reported.

At 400 mcg/m²: grade 2-3 nausea occurred in 2 patients (2 cycles) and grade 2 vomiting in one patient (1 cycle). Mild

15 local pain at porth-a-cath site, and mild alopecia were reported in one patient (1 cycle).

At 600 mcg/m²: grade 1-2 nausea in 2 patients (2 cycles), grade 2 fatigue in 1 patient (2 cycles) and mild alopecia in 1 patient (2 cycles) were reported.

20 At 800 mcg/m²: grade 1 nausea, fatigue, mucositis and fever occurred in 1 patient (1 cycle each).

No other grade 3-4 events were reported.

Mild to moderate (grade 1-2) increase in transaminases (attributable to the study drug) was observed at 200 mcg/m² (2/3 patients), at 400 mcg/m² (2/3 patients; a third patient showed a grade 2-3 transaminase elevation probably due to the IHA technology applied), and at 600 mcg/m² in 2 out of 3 patients. A grade 3 transaminase elevation was reported in the patient treated at 800 mcg/m².

30 The maximum transaminases elevation appeared during the first week after treatment. Grade 2 bilirubinemia increases were

observed starting from 100 mcg/m², but were not considered due to the study drug.

Other severe, non tumor related, laboratory abnormalities consisted of two grade 3 hyperglycemia observed in two 5 patients treated at 200 mcg/m² (persisting from baseline in one diabetic patient and being post prandial in the other patient).

Activity

Two objective tumor response were observed in liver at 200 10 mcg/m² in patients with HCC.

One patient had measurable liver disease at study entry followed by NMR (overall 17.75 cm²); after 2 IHA cycles, Partial Response (PR) was achieved (reduction by more than 86%); the PR was confirmed after the fourth IHA cycle and 15 became Complete Response (CR) after the sixth IHA cycle; the patient went off therapy and, at the moment, he is relapse-free and in follow-up.

The second patient presented multiple liver lesions at baseline (the bigger one was 6 cm diameter, evaluated by 20 Ctscan). Also in this case, PR was observed after 2 IHA cycles and confirmed after the third IHA cycle (the bigger lesion was decreased by 50% in diameter). Despite extrahepatic tumor progression (bone), the patient received another IHA treatment after which he was withdrawn from 25 therapy. Two months later liver Ctscan was repeated and the previous findings on the bigger lesions were confirmed while the smallest lesions were slightly increased.


In a third HCC patient treated at 800 mcg/m², a minor response was reported after 3 cycles.

30 These activity data show that the MMDX chemotherapy through the hepatic artery is effective for patients with liver cancers at a MMDX dosage much lower than that employed by

intravenous route, strongly reducing the dangerous systemic exposure and hence toxicity of MMDX.

CLAIMS

1. Use of methoxymorpholino doxorubicin (MMDX) of formula



5 in the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumour.

10 2. Use according to claim 1. wherein the liver tumor is a tumor primarily confined to the liver.

15 3. Use according to claim 2. wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. Use according to claim 1. wherein the tumor is a liver metastasis.

20 5. Use according to any one of the preceding claims wherein the intrahepatic administration of MMDX is via the hepatic artery.

6. Use according to any one of the preceeding claims wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

5 7. Use according to anyone of claims 1. to 6. wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

8. Use according to any one of the preceeding claims wherein MMDX is administered with an agent which remains 10 selectively in a liver tumor after its injection through the hepatic artery.

9. Use according to claim 8. wherein the agent is iodized oil.

15 10. Use according to anyone of the preceeding claims wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

20 11. Use according to claim 10. wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 800 mcg/m².

25 12. Use according to claim 11. wherein the dose is 200 mcg/m².

30 13. A pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery.

14. A pharmaceutical composition according to claim 13, wherein the agent is iodized oil.

15. Use of a pharmaceutical composition according to claim 5 13. or 14. for the treatment of a liver tumor.

16. Use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after 10 its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.

17. Use according to claim 16 wherein the agent is iodized 15 oil.

18. A method of treating a human liver tumor which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to a patient in need thereof. 20

19. A method for reducing MMDX systemic exposure of a patient suffering from a liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to said patient.



Case No.: 01-270

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF METHOXYMORPHOLINO DOXORUBICIN FOR THE TREATMENT OF A LIVER TUMOR

the specification of which is attached hereto unless the following space is checked:

was filed on August 27, 1999 as United States Application Serial Number 09/786,998.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

	<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>
1.	9820012.4	United Kingdom	14/09/98

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

	<u>Application Number</u>	<u>Filing Date</u>
1.		

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

	<u>Application Number</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
1.	PCT/EP99/06298	08/27/99	Entered national phase



I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and I direct that all correspondence be addressed to that Customer Number.

Customer Number: 020306

Principal attorney or agent: Stephen H. Docter
Telephone number: 312-913-0001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of first inventor: Maria Adele Pacciarini

Inventor's signature: Maria Adele Pacciarini Date: May 31, 2001
Residence: Milan, Italy ITX
Citizenship: IT
Post Office Address: Via degli Imbriani, 39, I-20158 Milan, Italy

2-00 Full name of second joint inventor: Olga Valota

Inventor's signature: Olga Valota Date: May 31, 2001
Residence: Legnano, Italy ITX
Citizenship: IT
Post Office Address: Via Nazario Sauro, 99, I-20025 Legnano, Italy

3-00 Full name of third joint inventor: David Kerr

Inventor's signature: David Kerr Date: May 31, 2001
Residence: Birmingham, United Kingdom GBX
Citizenship: GB
Post Office Address: 27 Westhill Road, Kings Norton, Birmingham B38 8TL, United Kingdom